The U.S. Court of Appeals for the Second Circuit raised the bar last week for when investors can sue companies for securities fraud over statements about clinical studies for products, securities litigation attorneys said.

A three-judge panel on Dec. 26 upheld the dismissal of a securities fraud lawsuit against Philip Morris International over the tobacco company’s statements characterizing its studies of the health benefits of one of its e-cigarettes as “rigorous” and “the best science.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]